Zenocutuzumab

Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.

Belfast-based Diaceutics has signed a multi-year contract worth up to £11.5 million with Partner Therapeutics to commercialize the oncology precision medicine BIZENGRI (zenocutuzumab).

A real-world study examined bispecific antibody use in relapsed/refractory multiple myeloma patients, revealing that 44.67% of evaluable patients received these agents in 2023.

Merus N.V. has achieved a significant milestone with the FDA approval of Bizengri, the first therapy for NRG1+ cancers, and reported encouraging Phase 2 data for Petosemtamab in treating HNSCC. These developments, alongside a strategic partnership with BHVN for new ADC programs, position Merus N.V. as a strong contender in the oncology space. The company's robust pipeline and financial health underscore its potential for growth in the coming years.

The five-year relative survival rate for pancreatic cancer has risen to 13%, marking the third consecutive year of improvement, yet it remains the lowest among major solid tumors.